Implementation of neuro-oncology service reconfiguration in accordance with NICE guidance provides enhanced clinical care for patients with glioblastoma multiforme. by Guilfoyle, Mathew et al.
Implementation of neuro-oncology service reconfiguration in
accordance with NICE guidance provides enhanced clinical
care for patients with glioblastoma multiforme
MR Guilfoyle1, RA Weerakkody1, A Oswal1, I Oberg1, C Jeffery1, K Haynes1, PJ Kullar1, D Greenberg2,
SJ Jefferies3, F Harris3, SJ Price1, S Thomson*,4,5 and C Watts*,1,5
1Cambridge University Department of Clinical Neurosciences, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0QQ, UK; 2Eastern Cancer
Registration and Information Centre, Magog Court, Shelford Bottom, Cambridge CB22 3AD, UK; 3Department of Oncology, Addenbrooke’s Hospital, Hills
Road, Cambridge CB2 0QQ, UK; 4Department of Neurosurgery, Leeds General Inf irmary, Leeds LS1 3EX, UK
BACKGROUND: Brain tumours account foro2% of all primary neoplasms but are responsible for 7% of the years of life lost from cancer
before age 70 years. The latest survival trends for patients with CNS malignancies have remained largely static. The objective of this
study was to evaluate the change in practice as a result of implementing the Improving Outcomes Guidance from the UK National
Institute for Health and Clinical Excellence (NICE).
METHODS: Patients were identified from the local cancer registry and hospital databases. We compared time from diagnosis to
treatment, proportion of patients discussed at multidisciplinary team (MDT) meetings, treatment received, length of inpatient stay and
survival. Inpatient and imaging costs were also estimated.
RESULTS: Service reconfiguration and implementation of NICE guidance resulted in significantly more patients being discussed by the
MDT—increased from 66 to 87%, reduced emergency admission in favour of elective surgery, reduced median hospital stay from
8 to 4.5 days, increased use of post-operative MRI from 17 to 91% facilitating early discharge and treatment planning, and reduced
cost of inpatient stay from d2096 in 2006 to d1316 in 2009. Patients treated with optimal surgery followed by radiotherapy with
concomitant and adjuvant temozolomide achieved outcomes comparable to those reported in clinical trials: median overall survival
18 months (2-year survival 35%).
CONCLUSIONS: Advancing the management of neuro-oncology patients by moving from an emergency-based system of patient referral
and management to a more planned elective outpatient-based pattern of care improves patient experience and has the potential to
deliver better outcomes and research opportunities.
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Each year in the UK over 4000 new cases of brain or central
nervous system cancers are diagnosed, B7 per 100 000 of the
population (Rachet et al, 2008). Although brain tumours account
foro2% of all primary neoplasms high mortality rates mean they
rank as the third leading cause of cancer-related death among men
aged 15–54 years and the fourth leading cause of cancer-related
death among women between 15 and 34 years of age (Kesari and
Stiles, 2006). Considered in terms of years of life lost brain
tumours are responsible for the highest cancer burden, with an
average of over 20 years lost per patient (Burnet et al, 2005).
The commonest primary brain tumours in adults are astro-
cytomas, of which the majority are malignant glioblastoma (GBM).
Survival trends for primary CNS malignancy have remained largely
static for many years, reflecting the general lack of effective
therapeutic options for patients with these cancers (Rachet et al,
2008). Clinical management of patients with GBM involves a
combination of surgery, radiotherapy and chemotherapy. Radio-
therapy has been the principle adjuvant modality since the late
1970s (Walker et al, 1978, 1980) with the addition of chemotherapy
demonstrating only modest benefit until recently (Stewart,
2002; Stupp et al, 2005). Current median life expectancy with
optimal treatment is 12–14 months, with approximately a quarter
of patients surviving 424 months (Stupp et al, 2005). There
clearly remains an unmet clinical need for new therapeutic
interventions.
Improving clinical outcomes not only requires the development
and application of more effective treatment but also better
organisation of the delivery of care (NICE, 2006). Historically,
patients with brain cancer have often experienced a fragmented
and uncoordinated pathway of care from diagnosis through to
treatment and follow-up. The prevailing pessimism towards the
efficacy of surgery for GBM contributed to a lack of prompt
treatment after diagnosis, a general policy of biopsy in preference
to resection, subtotal debulking when undertaken and little
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urgency in the commencement of adjuvant therapy. Recent
evidence has clearly demonstrated that substantial gains in
survival are possible with new advanced surgical techniques and
oncological management (Stupp et al, 2005; Stummer et al, 2006).
The maximal benefits of these developments will only be realised
with coordinated and specialised interdisciplinary care delivering
best-available treatment for each individual patient in a timely
manner. Alongside these changes in practice, health professionals
have an obligation to ensure patients can make informed decisions
about the complex treatment choices being presented to them. The
UK National Institute of Clinical Excellence (NICE), in its
Improving Outcomes Guidance (IOG) for people with brain and
other CNS tumours, has identified key aspects of neuro-oncology
services that need development (NICE, 2006). The principal
recommendations include establishing direct referral pathways,
multidisciplinary teams (MDTs) of neurosurgeons, oncologists,
pathologists and radiologists to review diagnoses and determine
appropriate treatment for every individual, supportive pre- and
post-operative counselling of patients and enhanced opportunities
for participation in clinical trials (NICE, 2006).
There is considerable evidence that centre and surgeon
subspecialisation has had significant benefits on the outcomes
for systemic cancers (e.g., breast and colon) (Gooiker et al, 2010;
van Gijn et al, 2010). Similarly, subspecialist paediatric neuro-
surgeons treating high caseloads of children with posterior fossa
tumours obtain better rates of gross tumour resection, a major
predictor of survival, and lower concomitant morbidity (Albright
et al, 2000). Developing the subspecialty of adult neurosurgical
oncology is an important component of the drive to improve
standards of care and patient safety, to facilitate the introduction
of new technologies and to promote and direct research. Dedicated
neurosurgical oncology clinics provide opportunities for patients
to discuss their management and consent to treatment, and also
promote enrolment in research such as tissue banking and
recruitment into clinical trials. The need for improvement is
highlighted by the fact that over the past decade there have been 13
open trials of novel therapies for paediatric brain tumours but only
4 open trials for adults on the National Cancer Research Network
(http://www.ncrn.org.uk/) trial portfolio.
NICE guidance has significant implications for the organisation
of neurosurgical services and has been variably adopted by the 34
neurosurgical units in the UK. Here, we describe how the guidance
was implemented and integrated within the Anglian Cancer
Network and the effects this had on clinical service delivery. To
set these developments in context, we have first established
outcomes for patients treated in the 10 years before the NICE
guidance. Second, we consider the potential problems and cost
implications of introducing an outpatient-based management
strategy without increasing delays in the patient pathway by
auditing the length of stay and the length of the patient journey
(from diagnostic scan to oncology management) before, during
and after the full implementation of the guidelines. Third, we
examine the realistic patient outcomes that are now achievable
with service reorganisation in combination with current optimal
surgical and adjuvant strategies.
METHODS
Outcome of patients treated 1997–2006
Patients were identified from the Eastern Cancer Registration and
Information Centre (ECRIC) database, which collects all confirmed
and suspected diagnoses of cancer from the Anglian Cancer
Network. This is the third largest cancer network in the UK with an
estimated population of over 2.66 million people (http://www.
ncin.org.uk). Addenbrooke’s Hospital, part of the Cambridge
University Hospital NHS Foundation Trust (CUHFT) is the
dedicated neurosurgical centre for this network. The ECRIC
database was queried for ICD-10 codes C71* and/or ICD-O-3
codes 94** for the period 1997–2006 to obtain the study sample.
Hospital pathology reports were then cross-checked to confirm
histological diagnosis of GBM. Patients with presumed diagnoses
on the basis of imaging but without histological confirmation were
excluded. Data collected included gender, date of birth, date of
diagnosis, date of death and whether radiotherapy and/or
chemotherapy were received in the first 6 months after diagnosis.
Surgical procedure (stereotactic biopsy vs craniotomy and
debulking) was queried from the operating department database.
Implementation of NICE guidelines and current treatment
outcomes
Changing the neuro-oncology service in accordance with the NICE
guidance evolved as an iterative process. First, a weekly multi-
disciplinary meeting was convened and the core members from
each subspecialty were identified and attendance registered. A
dedicated neurosurgical oncology clinic was established and
scheduled for the afternoon on the same day to review new and
follow-up patients discussed at the MDT. The second development
involved changing the pattern of referral while maintaining patient
safety. All physicians referring patients with suspected brain
tumours completed a proforma designed to facilitate data
collection transmitted electronically to the MDT coordinator (see
Supplementary Material). All cases were first discussed with the
on-call neurosurgical team to ensure genuine emergencies (e.g.,
cerebral abscess) were managed appropriately.
To evaluate change in practice resulting from the NICE IOG, we
examined the management of patients during the 6 months
immediately before the report (February to July 2006) and
compared findings with two 6-month periods following publica-
tion (April to November 2008 and the same period in 2009). A
number of indicators in the treatment pathway relating to key
recommendations in the NICE guidance were examined, specifi-
cally proportions of cases discussed at MDT before and after
surgical treatment, time from referral to MDT discussion,
treatment, and histopathology result, length of inpatient stay and
proportion of patients managed as elective admissions as opposed
to emergency transfers.
Data were retrieved from the MDT database and supplemented
with case-note data. We calculated the cost of inpatient stay and
imaging using a standard unit cost for a bed-day of d262 and unit
cost for an MRI scan of d137, derived from the hospital business
intelligence system.
Difficulties in implementing the IOG included ensuring that the
clinical details forwarded to the MDT were adequate to allow a
consensus decision on appropriate treatment. So that sufficient
data were collected a standardised proforma with a minimum data
set was developed (see Supplementary Material). To facilitate the
specialisation of surgical practice, we implemented a process of
clinical governance to maintain efficient and safe patient manage-
ment. The introduction of routine post-operative MRI scans within
72 h further served as a tool for audit of surgical standards, and the
images were incorporated into treatment planning by the clinical
oncologists. Earlier discharge of patients within 48–72 h of surgery
offset additional imaging costs.
Outcomes of contemporary adjuvant treatment
For comparison against the historical data, we examined survival in
patients currently receiving IOG compliant maximal surgical and
adjuvant therapy, that is, debulking of the tumour where possible
followed by concomitant radiotherapy and temozolomide chemother-
apy (RT-TMZ) and subsequent further adjuvant temozolomide.
Statistical analysis was performed in SPSS 18.0 (IBM, Middlesex,
UK). Survival was estimated with the Kaplan–Meier method and
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compared between groups with the log-rank test. Cox-regression
analysis was used to identify predictors of survival. Continuous
variables were compared with the Mann–Whitney U-test and
dichotomous variables compared with the w2-test. Results were
considered significant at the 5% level.
RESULTS
Improving outcomes before NICE guidance
From 1997 to 2006, a total of 685 patients were diagnosed with
histologically proven GBM. Mean age was 60.7 years (s.d. 11.4,
median 62) and a majority of patients were male (61.0%).
Overall median survival for all patients was 5.03 months (95% CI
4.56–5.50; Table 1, Figure 1A). Univariate analyses (Table 1)
showed significantly longer survival for patients receiving debulk-
ing surgery over stereotactic biopsy (median 6.6 vs 3.8 months,
Po0.001; Figure 1C), radiotherapy (median 7.8 vs 2.0, Po0.001;
Figure 1D), and sequential radiotherapy and chemotherapy,
typically a procarbazine, lomustine (CCNU), and vincristine
(PCV) regimen (median 14.5 vs 4.2 months, Po0.001;
Figure 1D). As expected there was an inverse association between
survival and age (mediano45 years: 14.1 months, 45–54 years: 8.3
months, 55–64 years: 5.6 months, 65–74 years: 3.7 months,
475 years: 2.8 months, Po0.001; Figure 1B).
The first (1997–2001) and latter (2002–2006) halves of the study
period were compared to assess changes in practice and outcome
(Figure 2). There was no change in patient age (mean 61.5 vs
59.8 years, t¼ 1.95, P40.05) or gender (male: 58.9% vs 63.7%,
w2¼ 1.7, P40.05). However, there were significant increases in the
proportions of patients receiving debulking surgery (39.9% vs 54.8%,
w2¼ 13.8, Po0.001), adjuvant radiotherapy (59.4% vs 66.8%, w2¼ 3.9,
P¼ 0.048) and chemotherapy (10.4% vs 28.0%, w2¼ 20.2, Po0.001;
Figure 2A). There was a significant improvement in survival between
the two 5-year periods (4.4 vs 5.8 months, Po0.001; Figure 2B). Cox-
regression analysis showed the independent predictors of survival
were age (Hazard ratio (95%CI): 1.03 (1.02–1.04), Po0.001),
debulking surgery (HR 0.80 (0.67–0.94), Po0.01), radiotherapy
(HR 0.43 (0.36–0.51), Po0.001) and chemotherapy (HR 0.59
(0.46–0.75), Po0.01). Gender and year of diagnosis were not
significantly associated with survival in the model.
Implementation of NICE guidelines
Over a period ofB10 months, the surgical management of neuro-
oncology patients was gradually transferred to three of the ten
consultant neurosurgeons and the neurosurgical oncology clinic
was firmly established. Neuro-oncology was formally defined as a
Table 1 Historical survival of GBM patients
Survival (months) Survival (%)
Subgroup n Median (95% CI) Mean (95% CI) 6 months 12 months 24 months
All patients 685 5.0 (4.6–5.5) 8.7 (7.6–9.8) 44 20 6
Age (years)
o45 63 14.1 (7.4–20.9) 25.1 (16.6–33.5) 75 54 31
45–54 112 8.3 (6.3–10.2) 9.9 (8.4–11.5) 60 34 8
55–64 229 5.6 (5.0–6.3) 7.3 (6.4–8.2) 45 16 2
65–74 226 3.7 (3.1–4.2) 5.6 (4.8–6.5) 30 12 2
X75 55 2.8 (2.0–3.5) 3.6 (2.8–4.4) 24 2 0
Surgery
Biopsy 333 3.8 (3.3–4.4) 6.2 (5.4–6.9) 34 14 3
Debulking 324 6.6 (5.7–7.5) 11.3 (9.1–13.5) 53 26 9
Adjuvant treatment
None 251 2.0 (1.7–2.3) 3.8 (3.0–4.6) 14 6 2
Radiotherapy 329 6.2 (5.5–7.0) 9.2 (7.7–10.6) 51 17 5
Chemoradiotherapy 105 14.5 (13.0–16.0) 17.4 (14.4–20.4) 90 62 15
Time
1997–2001 360 4.4 (4.0–4.9) 6.8 (5.9–7.7) 38 15 3
2002–2006 325 5.8 (5.1–6.5) 10.2 (8.6–11.7) 49 25 9
Abbreviations: CI¼ confidence interval; GBM¼ glioblastoma.
0.8
0.6
Su
rv
iva
l
0.4
0.2
0.0
0 12 24 36 48 60
Months
0 12 24 36 48 60
Months
0 12 24 36 48 60
Months
0 12 24 36 48 60
Months
Biopsy None
<45
45–54
55–64
65–74
>75
RT
RT + CTDebulking
1.0
0.8
0.6
Su
rv
iva
l
0.4
0.2
0.0
1.0
0.8
0.6
Su
rv
iva
l
0.4
0.2
0.0
1.0
0.8
0.6
Su
rv
iva
l
0.4
0.2
0.0
1.0
Figure 1 Survival for historical cohort. Kaplan–Meier curves for patients
with GBM diagnosed 1997–2006. Survival of all patients (A), stratified by
age (B), comparing stereotactic biopsy and tumour debulking (C) and
comparing sequential radiotherapy and chemotherapy (D).
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neurosurgical subspecialty, eventually leading to the appointment
of a clinical lead for neuro-oncological surgery in September 2007
and an additional neurosurgeon with a subspecialty interest in
neuro-oncology was appointed in April 2008. The surgeons
specialising in neuro-oncology easily fulfilled the IOG requirement
for 450% of a surgeon’s practice to comprise tumour work.
Thirty-five patients were diagnosed with GBM during period 1
(February to July 2006) increasing to 49 and 45 in periods 2 (April to
November 2008) and 3 (April to November 2009), respectively (total
n¼ 129). The proportion of cases reviewed at an MDT meeting
before surgery significantly increased (66–87%, P¼ 0.027;
Figure 3A). The proportion of patients undergoing MRI within
72 h of tumour debulking increased from 17 to 91% (Po0.001;
Figure 3A). In period 1, most patients were admitted for surgery as
emergencies, whereas in both periods 2 and 3 the majority were
admitted electively as urgent (not emergency) cases (Po0.001;
Figure 3B). Median length of stay was 8 days in period 1, decreasing
to 4.5 days in period 3 (P¼ 0.004; Figure 3C). Median time for
histopathology reporting decreased from 6 to 3 days (Po0.001); all
cases and results were reviewed at a post-operative MDT meeting.
Overall time from referral imaging to post-operative MDT remained
unchanged (median 23 days; P¼ 0.61). The proportion of patients
receiving their diagnosis in a specialist neuro-oncology clinic
increased from 65 to 100% (Po0.001) and the time from operation
to outpatient review significantly decreased (median 17 vs 10 days;
Po0.001). At the same time, we observed a significant trend in
reducing total cost of inpatient stay and imaging (median costs 2006:
d2096, 2008: d1048, 2009: d1316, Po0.01; Figure 3D).
Outcomes of contemporary optimal treatment
The implementation of RT with concomitant and adjuvant TMZ
occurred in April 2005 following specific CUHFT approval and
funding on an individual patient basis, predating the NICE
technology appraisal by 2 years (NICE, 2007). From 2005 to
2008, 49 patients aged 26–68 years (mean 56) were commenced on
the RT-TMZ protocol. Consistent with published data, 92%
completed the concomitant phase and 42% completed the adjuvant
phase of treatment. Patients not receiving TMZ were managed with
sequential radiotherapy and PCV chemotherapy according to
standard best practice. Outcomes were similar to the 2002–2006
cohort and the data were not analysed further.
Patients for RT-TMZ were selected as per the original Stupp trial
protocol (Stupp et al, 2005). All were WHO performance status
0 or 1 with mean age 56 years, and 80% had undergone debulking
surgery. Of those starting combined therapy 43 (88%) completed
the concomitant TMZ; treatment was discontinued in three
patients due to abnormal liver function tests, two due to
thrombocytopaenia and one was unable to tolerate TMZ because
of nausea. Twenty-four patients (53%) did not complete the
adjuvant phase of TMZ treatment due to evidence of radiological
progression in 9 and clinical progression in 10, deranged liver
enzymes in 2 patients, significant Herpes Zoster infection in 2 and
intolerance in 1. Median overall survival (OS) and clinical
progression-free survival (PFS) were 18 and 12 months, respec-
tively, with 2-year survival of 35% (Figure 4).
DISCUSSION
We present data showing how implementation of NICE IOG for
service organisation together with advances in management has
delivered improved standards of care and overall outcome for
patients with GBM. Before the introduction of the IOG in 2006,
there was a modest improvement in patient survival in the period
2002–2006 compared with 1997–2001. This was associated with
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increased access to surgical debulking, radiotherapy and chemo-
therapy, which were also independent predictors of survival,
consistent with earlier observational studies and randomised trials
(Curran et al, 1993; Brenner and Rachet, 2004; Stupp et al, 2005;
Pichlmeier et al, 2008; Rachet et al, 2008).
Publication of the NICE guidance on improving the process of
care for patients with CNS malignancies coincided with the advent
of new evidence-based surgical techniques and oncological
therapies in the first half of the last decade. These developments
provided the impetus to re-evaluate and restructure brain tumour
service provision for the Anglian Cancer Network. The existing
patient pathway of care was mapped to define the pattern of
referrals to the neurosurgical service and to identify how this could
be changed to facilitate referrals to a single specialised neuro-
surgical clinic in line with NICE guidance. The neuro-oncology
MDT was designated as the primary route of referral for all new
brain tumour diagnoses and appropriate data collection imple-
mented.
The development of a surgeon-led subspecialist clinic involving
clinical nurse practitioners (CNPs) following each MDT meeting
facilitated rapid review of patients to discuss diagnosis and
management. Three dedicated oncology neurosurgeons and two
neuro-oncology CNPs support the clinic enabling it to run
uninterrupted every week. This has been fundamental in the
transition from a system predominantly of inpatient transfers from
district hospitals, to an outpatient-based service.
At a patient’s initial clinic visit sufficient time is allotted for
introduction to the team members, for in-depth discussion of
provisional diagnosis and recommended management, and to
begin the process of consent using procedure-specific consent
forms and clear written material provided before admission for
surgery (see Supplementary Material). Histological reports are
generally discussed at the MDT the week after surgery and patients
attend the clinic the same day to be informed of their diagnosis.
At the follow-up post-operative clinic appointments difficult
information, chiefly histopathology results and prognosis, are
communicated in a familiar environment by clinicians the patient
has met previously. There is also opportunity for wound
assessment, removal of clips or sutures as necessary, weaning of
steroids and review of anti-convulsants. Contact details of the
CNPs are provided for ongoing support at home and to address
any questions. Logistically, the clinic facilitates planning of
operating lists well in advance, better coordination of pre-
operative imaging, day-of-surgery admissions and overall more
efficient utilisation of theatre time by minimising cancellations.
Discharge planning can also start before admission with the focus
on returning home rather than to local hospitals. Safe but early
discharge has become the objective of occupational and phy-
siotherapists, and the expectation of patients. The measures put in
place have contributed to a streamlined service in which patients
remain at home for longer, obtain treatment that is based on up to
date evidence, and are able to discuss their condition in the privacy
of a clinic.
The benefits of enhancing the role of pre- and post-operative
MDT and restructuring the system as an outpatient-based service
may potentially come at the expense of increasing delays in
management, for example, from diagnostic scan to treatment. In
practice, the present data demonstrate that length of stay and time
from surgery to definitive pathology reporting have both been
significantly reduced, and the proportion of patients having post-
operative MRI within 72 h has increased. Furthermore, in
conjunction with the shift from an emergency to an elective-based
process of patient admission these measures have resulted in a net
cost reduction per patient. Previous studies have suggested that
neurosurgical oncology subspecialisation is of limited benefit
(Latif et al, 1998), but this observation is at odds with evidence
from other clinical oncology disciplines (Gooiker et al, 2010; van
Gijn et al, 2010). Our data generate the testable hypothesis that an
integrated specialist process of care will improve the patient
experience and provide a platform to gather this data.
The litmus test of any service restructuring will be improved
survival of patients in the long term. Our early experience with
combining aggressive surgical resection and adjuvant chemo-
radiotherapy with temozolomide has been very favourable. We
found a median OS, median PFS and 2-year survival of 18 months,
12 months and 35%, respectively. This is comparable to the Stupp
trial which reported an OS of 14.6 months, a PFS of 7 months and a
2-year survival of 26.5% (Stupp et al, 2005). Of note, our data
more closely mirror the subgroup of trial patients in whom a
complete surgical resection was obtained whose OS was 18.8
months and 2-year survival of 38.4% (Stupp et al, 2009). The
acquisition of early post-operative baseline MRI allowed better
recognition and differentiation of tumour progression and
pseudoprogression so that patients did not have their adjuvant
temozolomide terminated prematurely (de Wit et al, 2004;
Chamberlain et al, 2007). These data represent a highly selected
cohort from a single cancer network and cannot be extrapolated to
a broader population. Nevertheless, they show that the service is
able to deliver outcomes comparable to those achieved within a
clinical trial setting.
GALA-5 trial (CRUK)
Maltings trial (NIHR)
If very urgent
Referrer Probable glioma
Glioma clinic
± pre-op assessment
Surgery
MDT
Glioma clinic
(diagnosis)
MDT
OncologyPalliative care
Consultant reviews scans
Research
studies
Research
studies
Research
studies
Tissue
banking
CLINICAL
TRIALS
3 EORTC trials: BR13,
BR14, RT in Atypical
Meningioma  
Figure 5 Service reconfiguration supports research for patient benefit. Our ability to interrogate each stage of the patient journey with an array of
screening, diagnostic and analytical tools is unique. This results in a highly integrated research infrastructure capable of delivering tangible results evidenced by
the number of clinical studies into which we are recruiting patients. NB: RT in Meningioma, MALTINGS and GALA-5 are all led by Cambridge PIs.
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More recently, fluorescence-guided surgical resection has been
introduced and an increasing proportion of patients are receiving
carmustine chemotherapy wafer implants after debulking (Westphal
et al, 2003; Stummer et al, 2006). The improvements made in the
system of care will ensure that all patients eligible for these advanced
interventions are offered current best treatment. The introduction of a
dedicated referral pathway, specialist MDT meetings and routine post-
operative imaging has established a robust mechanism for rigorous
surgical, radiological and chemotherapy audit and provides the
necessary platform for continued research and recruitment into
clinical trials (Figure 5). The latter benefit is evidenced by the opening
of a NIHR-funded observational study imaging tumour invasion
(MALTING Study; UKCRN 8596) and a CRUK/SDBTT funded phase 1
study combining intraoperative chemotherapy with fluorescence-
guided resection (GALA-5; CRUK/10/009). Improved access to tissue
has enabled us to refine a protocol for efficient derivation of stem-like
tumour initiating cells from GBM and to develop pre-clinical animal
models for drug development and testing (Fael Al-Mayhani et al, 2009).
We show that neurosurgical oncology services can be reconfi-
gured from an unplanned, consultant centric, research ambivalent
process of care into an outpatient-based, consultant led, patient-
centred, research-orientated practice. We have established that
these changes are cost effective. Our experience suggests that wider
implementation of NICE IOG-based models of service delivery will
benefit patients, clinicians, researchers and primary care commis-
sioners.
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